Kezar Life Sciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Hold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy Concerns
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)
Kezar Life Sciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Kezar Life Sciences Analyst Ratings
Analysts' Top Healthcare Picks: DocGo (DCGO), Kezar Life Sciences (KZR)
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Kezar Life Sciences Analyst Ratings
Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $2
Kezar Life Sciences Analyst Ratings
Hold Rating for Kezar Life Sciences Amid Uncertainty: An Analysis of Management Changes, Drug Trials, and Financial Prospects
Analysts Are Bullish on Top Healthcare Stocks: Antibe Therapeutics (ATBPF), Kezar Life Sciences (KZR)
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Kezar Life Sciences Analyst Ratings
Restructuring and Clinical Progress Bolster Kezar Life Sciences' Buy Rating: An Analysis
Kezar Life Sciences Analyst Ratings
HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $20
Kezar Life Sciences Analyst Ratings